Soleno Therapeutics, Inc. (SLNO)

Market Cap	1.28B
Revenue (ttm)	n/a
Net Income (ttm)	-38.99M
Shares Out	32.46M
EPS (ttm)	-2.36
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	329,314
Open	40.74
Previous Close	40.14
Day's Range	39.20 - 40.74
52-Week Range	3.16 - 53.82
Beta	-1.54
Analysts	Strong Buy
Price Target	55.60 (+41.33%)
Earnings Date	May 7, 2024

About SLNO

Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, Califor...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Nov 13, 2014
• Employees: 33
• Stock Exchange: NASDAQ
• Ticker Symbol: SLNO

Analyst Forecast

According to 5 analysts, the average rating for SLNO stock is "Strong Buy." The 12-month stock price forecast is $55.6, which is an increase of 41.33% from the latest price.

Price Target

$55.6

(41.33% upside)

Analyst Consensus: Strong Buy